Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

Academic Article

Abstract

  • We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.
  • Published In

    Keywords

  • Acquired Immunodeficiency Syndrome, Adenine, Adolescent, Adult, Aged, Anti-HIV Agents, Benzoxazines, CD4 Lymphocyte Count, Deoxycytidine, Drug Resistance, Viral, Drug Therapy, Combination, Emtricitabine, Female, HIV-1, Humans, Male, Middle Aged, Organophosphonates, Pyrrolidinones, Raltegravir Potassium, Tenofovir
  • Digital Object Identifier (doi)

    Author List

  • DeJesus E; Rockstroh JK; Lennox JL; Saag MS; Lazzarin A; Zhao J; Wan H; Rodgers AJ; Walker ML; Miller M
  • Start Page

  • 228
  • End Page

  • 232
  • Volume

  • 13
  • Issue

  • 4